Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Recommended Reading Pfizer marks progress for successor sickle cell drug at ASH Pfizer is pulling the sickle cell disease drug Oxbryta off the market and ending clinical trials of the medicine ...

Pfizer’s startling announcement late Wednesday that it would pull its pill for sickle-cell disease off pharmacy shelves is a blow to the drugmaker’s efforts to buy its way through an impending ...

If you've experienced serious side effects from Oxbryta, find out if you qualify for compensation. CHEYENNE, WY / ACCESSWIRE / October 23, 2024 / InjuryClaims.com is connecting people who may have ...

says BMO Capital CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher Leerink sees little ...

Oxbryta, one of at least six treatments for the disease, is mostly used in patients with mild-to-moderate symptoms. The drug received accelerated approved in the U.S. in 2019, requiring further trials ...

Pfizer PFE announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved. Why PFE is Withdrawing the ...